When Processing, Not Presence, Determines Visibility

The assumption that antigen presentation is primarily a function of protein abundance has always been an attractive simplification. In the case of p53, this assumption becomes even more tempting: a stress-activated protein, stabilized in tumors, transcriptionally active, and deeply embedded in the machinery of cellular surveillance. If any protein should be visible to the immune system, it should be p53.

Yet the emerging evidence suggests something more nuanced. What determines whether p53 is seen is not its abundance, but whether its fragments survive a highly selective intracellular processing environment long enough to be displayed.

This distinction, hinted at in earlier work examining the natural ligandome of HLA-C alleles, becomes far more consequential when viewed alongside recent population-scale genetic findings. In the Codondex analysis of 2022, a TP53-derived peptide—TAKSVTCTY—was identified among ligands presented by HLA-C*02:02, alongside tumor-associated antigens such as MAGEA3. That observation traces back to immuno-peptidomic work characterising HLA-C motifs and naturally presented ligands, where TP53-derived peptides were directly eluted from HLA complexes.

The implication was straightforward: p53 can, at least under some conditions, enter the HLA-C presentation pathway. But, this observation left unresolved a deeper question. If the peptide can bind, why is there so little evidence of dominant immune responses driven through this route?

A partial answer emerges when we contrast this with the much more extensively validated role of HLA-A*02:01. Across multiple studies, p53-derived epitopes presented by HLA-A*02:01 consistently generate measurable CD8⁺ T-cell responses, including classic epitopes such as p53₍264–272₎ (LLGRNSFEV) and related variants (see for example: https://pubmed.ncbi.nlm.nih.gov/10811890/ and https://pubmed.ncbi.nlm.nih.gov/24504111/). This allele appears repeatedly in vaccine design, adoptive T-cell strategies, and immuno-peptidomic datasets. It behaves, in effect, as a reliable conduit between intracellular mutation and immune recognition.

The difference between these two alleles is not simply one of binding affinity. It is a difference in how the intracellular system prepares peptides before they ever encounter the HLA binding groove.

The recent study published in Nature does not mention p53 directly, but it introduces a critical shift in how we should think about antigen presentation. By examining viral DNA loads across large human cohorts, the study demonstrates that variation in antigen presentation is strongly influenced not only by HLA alleles themselves, but by upstream processing enzymes—most notably ERAP1 and ERAP2. These enzymes trim peptide precursors within the endoplasmic reticulum, effectively determining which peptides reach the optimal length and composition required for stable HLA binding. Their functional importance has been demonstrated mechanistically in earlier work showing how ERAP variants reshape the immuno-peptidome (for example: https://www.nature.com/articles/ng.2558 and https://pubmed.ncbi.nlm.nih.gov/21804560/).

This introduces a gating mechanism that sits upstream of presentation. A peptide may be theoretically compatible with an HLA allele, yet never appear on the cell surface if it is over-trimmed, under-trimmed, or otherwise destabilized during processing.

Seen through this lens, the difference between HLA-A02:01 and HLA-C02:02 becomes more intelligible. HLA-A*02:01 appears to sit in a favorable position within this processing landscape. Its binding motif aligns well with peptides commonly generated by proteasomal cleavage and refined by ERAP trimming, as demonstrated in motif and structural studies of peptide–MHC stability. The result is a relatively high probability that suitable p53-derived peptides will survive the journey from cytosol to cell surface.

HLA-C*02:02, by contrast, operates under tighter constraints. Its peptide-binding preferences are narrower, and its expression levels on the cell surface are lower. More importantly, it appears more sensitive to the exact output of ERAP-mediated trimming. A peptide such as TAKSVTCTY may exist as a valid ligand, but whether it is produced consistently and in sufficient quantities may depend on subtle variations in ERAP1 and ERAP2 activity.

This introduces a form of biological contingency. In one individual, a TP53-derived peptide may be efficiently trimmed and presented by HLA-C*02:02. In another, the same peptide may be degraded before it ever reaches the binding groove. The difference is not in the tumor, nor in the TP53 sequence itself, but in the inherited configuration of the antigen-processing machinery.

What makes HLA-C particularly interesting is that its role extends beyond classical T-cell presentation. Unlike HLA-A, HLA-C molecules are primary ligands for killer immunoglobulin-like receptors (KIRs) on natural killer cells. This means that the peptide presented by HLA-C can influence not only whether a T cell recognizes a target, but whether an NK cell is inhibited or activated. Importantly, peptide sequence itself can modulate KIR binding affinity, introducing a second layer of regulation beyond simple HLA presence.

In this context, a TP53-derived peptide presented by HLA-C*02:02 may have a dual function. It may serve as a weak or conditional T-cell antigen, while simultaneously modulating NK cell behavior through peptide-dependent effects on KIR binding. The immune consequence of p53 presentation through HLA-C may therefore be less about direct cytotoxic targeting and more about altering the threshold at which NK cells engage.

This possibility reframes the earlier observation. The presence of a TP53 peptide in the HLA-C*02:02 ligandome is not simply evidence of presentation; it may represent a regulatory signal embedded within the innate immune interface.

The 2026 findings reinforce this interpretation by showing that small differences in HLA and ERAP combinations can produce measurable differences in viral control at the population level. If such differences can influence the handling of persistent viral DNA, as shown in the Nature study, it is reasonable to infer that they could also shape the presentation of endogenous stress signals such as p53.

What emerges is a layered model. HLA-A02:01 represents a pathway of efficiency and dominance: peptides are reliably generated, stably presented, and frequently recognized. HLA-C02:02 represents a pathway of conditionality: peptides may be presented, but only under specific processing conditions, and with consequences that extend into NK cell regulation.

Within this framework, p53 is not a single antigenic entity but a source of potential signals whose visibility depends on the alignment of multiple systems—proteasomal cleavage, ERAP trimming, HLA binding, and receptor engagement on immune cells.

This aligns closely with the broader Codondex perspective, in which sequence context—particularly intronic and repetitive elements—may influence not only transcriptional behavior but also downstream processing dynamics. If short RNA or peptide fragments derived from TP53 can alter condensate formation or proteostasis, as discussed in related Codondex work, they may also indirectly influence which peptides are generated and presented.

The question is no longer whether p53 can be presented by a given HLA allele. That has already been answered in the affirmative for both HLA-A02:01 and HLA-C02:02. The more precise question is under what intracellular conditions that presentation becomes stable, visible, and immunologically consequential.

It is within this narrower and more mechanistically grounded space that new opportunities emerge—particularly in understanding how antigen processing variability might be leveraged, or corrected, to expose signals that are otherwise hidden in plain sight.

Natural Killers, Mitochondria, p53, and Parkinson’s

The emerging landscape of neuro-immune communication reveals that the traditional boundaries between immune sentinel function and neuronal integrity are far less distinct than once imagined. One useful framework for understanding Parkinson’s disease (PD) begins with environmental triggers, particularly persistent toxins such as dioxins and related xenobiotics. These compounds can initiate a molecular cascade: toxin exposure → mitochondrial dysfunction → oxidative stress → p53 activation → neuronal apoptosis. Embedded within this cascade is a regulatory layer involving bHLH-PAS transcription factor complexes, including AHR–ARNT and HIF1A–ARNT, which bind promoter elements containing GCGTG/GCTGTG motifs and coordinate cellular responses to environmental and metabolic stress. The toxicological effects of dioxins are largely mediated through activation of the aryl hydrocarbon receptor (AHR) transcription pathway (see research overview: https://espace.library.uq.edu.au/view/UQ%3A382961).

Within this molecular framework lies another equally compelling axis: the role of Natural Killer (NK) cells as innate effectors at the neuro-immune interface. These cells, capable of homing to inflamed neural tissue and scavenging pathological aggregates such as α-synuclein, emerge not as passive bystanders but as regulators of disease progression. Experimental work has demonstrated that NK cells can internalize and degrade extracellular α-synuclein aggregates, and that NK-cell depletion significantly worsens synuclein pathology in mouse models of Parkinson’s disease (Nature Communications research summary: https://pmc.ncbi.nlm.nih.gov/articles/PMC6983411/).

NK cells are uniquely positioned to influence neural landscapes because they bridge innate immunity with neuronal signaling. They communicate not only through cytotoxic mechanisms but also through synapse-like contacts and cytokine signaling that mirror the bi-directional dialogue inherent to neural circuits. Reviews of immune mechanisms in PD increasingly highlight NK cells as modulators of neuroinflammation and α-synuclein pathology (Frontiers in Aging Neuroscience review: https://www.frontiersin.org/articles/10.3389/fnagi.2022.890816/full).

This neuro-immune unit invites us to see PD not solely as a problem of intrinsic neuronal failure, but as a disturbance in the regulatory network connecting environmental sensing, immune surveillance, and neural homeostasis.

At the center of this network sits the aryl hydrocarbon receptor (AHR), a toxin-sensing transcription factor activated by environmental pollutants such as dioxins and polycyclic aromatic hydrocarbons. Once activated, AHR forms a heterodimer with ARNT and binds regulatory DNA elements containing GCGTG-type motifs, initiating transcriptional programs that reshape metabolism and stress responses. A parallel sensing system operates through HIF1A, another bHLH-PAS transcription factor that binds related RCGTG/GCGTG promoter motifs during mitochondrial dysfunction or oxygen imbalance. Importantly, studies show substantial crosstalk between AHR and HIF signaling pathways, allowing environmental toxins and metabolic stress to converge on shared transcriptional targets (Life Science Alliance research: https://pmc.ncbi.nlm.nih.gov/articles/PMC9896012/).

For neurons—particularly the metabolically fragile dopaminergic neurons of the substantia nigra—persistent activation of toxin-responsive pathways can have profound consequences. Xenobiotic metabolism generates oxidative stress and mitochondrial injury, activating p53, the master regulator of cellular stress responses. As explored in earlier Codondex work on mitochondrial signaling and p53-regulated RNA networks, mitochondrial dysfunction and p53 activation are tightly intertwined components of cellular stress adaptation.

But these pathways do not operate only within neurons. p53 signaling and mitochondrial health also influence immune cells, including NK cells. NK cells rely heavily on mitochondrial metabolism for effective surveillance, cytokine production, and cytotoxic function. When toxin exposure disrupts mitochondrial integrity systemically, it may impair the very immune cells responsible for clearing damaged neurons and pathological protein aggregates.

Recent studies confirm that NK cells are present in brains affected by PD and may influence disease course, scavenging α-synuclein aggregates and modulating neuroinflammation. Experimental depletion of NK cells exacerbates synuclein pathology and inflammatory responses in PD models (Cellular & Molecular Immunology study: https://www.nature.com/articles/s12276-020-00505-7).

Viewed through the lens of toxin vulnerability, the cascade becomes clearer:

Environmental neurotoxicants such as dioxins activate AHR, engaging GCGTG-containing promoter elements and reshaping transcriptional programs governing metabolism and inflammation. Toxin-induced mitochondrial dysfunction stabilizes HIF1A, reinforcing stress-adaptation pathways.

In neurons, these converging signals activate p53-dependent apoptotic programs, leading to dopaminergic neuron loss.

In immune cells, including NK cells, mitochondrial impairment and p53 signaling influence metabolic fitness and cytokine output.

Thus the integrity of mitochondrial networks becomes a common currency between neuronal survival and immune effector competence. Rather than viewing PD strictly as a neuronal degenerative disorder, integrating environmental toxin sensing with immune biology suggests a broader model in which:

Environmental pollutants such as dioxins and related xenobiotics prime cellular stress responses through AHR-mediated transcription. These signals converge with HIF1A and p53 pathways, amplifying mitochondrial dysfunction.

NK cells and other innate lymphocytes respond to neuronal danger cues and help clear pathological aggregates, but their effectiveness is constrained when toxin exposure disrupts systemic mitochondrial health. In this perspective, Parkinson’s disease emerges as a neuro-immune network disorder shaped by environmental vulnerability, where toxin sensing, mitochondrial integrity, transcriptional stress responses, and immune surveillance converge.

Mitochondria, Natural Killer's, P53 in Autoimmunity, Cancer and Disease

 

Key Points

• Research suggests mitochondria may contribute to NK cell dysfunction in cancer, linked to p53 mutations.
• It is likely that p53 alterations affect NK cell recognition via ULBP1 and ULBP2, influenced by genetic disruptions.
• The evidence leans toward transposable elements and viruses impacting p53, potentially worsening NK cell function.

Introduction

Mitochondria play a crucial role in the function of natural killer (NK) cells, which are vital for fighting cancer. When these cells don't work properly, cancer can spread more easily, especially in conditions tied to autoimmune cells. This response explores how mitochondria might be a leading cause of NK cell dysfunction in cancer, focusing on the tumor suppressor gene p53, and how genetic factors like transposable elements and viruses could play a role. We'll also look at how changes in p53, particularly in its intron 1 and coding DNA, relate to NK cell ligands ULBP1 and ULBP2, affecting overall cellular balance and potentially leading to tumor growth.

Mitochondria and NK Cell Dysfunction

Mitochondria are essential for NK cells, providing energy for their cancer-fighting activities. Studies show that after cancer surgery, NK cells often have reduced mitochondrial membrane potential, which correlates with lower cytotoxicity, meaning they struggle to kill cancer cells. This dysfunction can be worsened by the tumor microenvironment, where cancer cells compete for nutrients, creating conditions like hypoxia and high lactate levels that impair NK cell metabolism.

The Role of p53

p53 is a key gene that helps prevent cancer by controlling cell growth and death, and it also influences mitochondrial function. In cancer cells, mutations in p53 can lead to mitochondrial issues, shifting metabolism toward glycolysis and producing factors that suppress the immune system. Importantly, p53 helps NK cells by regulating ULBP1 and ULBP2, proteins on cancer cells that NK cells recognize to attack them. When p53 is mutated, this recognition fails, allowing cancer cells to evade NK cells.

Genetic Disruptions: Transposable Elements and Viruses

Transposable elements, like endogenous retroviruses, and viruses can disrupt p53's function by altering its binding sites or regulatory regions. For example, these elements can insert into p53's intron 1, affecting how it controls genes like ULBP1 and ULBP2. This disruption can lead to genetic instability, making cancer cells harder for NK cells to detect and worsening the tumor microenvironment, which further impairs NK cell mitochondrial health.

---

Analysis of Mitochondria, p53, and NK Cell Dysfunction in Cancer

Mitochondrial Function and NK Cell Dysfunction

Mitochondria are critical organelles for NK cell effector functions, providing energy through oxidative phosphorylation (OXPHOS) and supporting metabolic processes necessary for cytotoxicity and cytokine production. Research has shown that mitochondrial dysfunction, particularly a decrease in mitochondrial membrane potential (ΔΨm), is associated with impaired NK cell activity. For instance, studies on post-cancer surgery patients reveal that major surgeries, such as intrathoracic esophagectomies, lead to significant drops in ΔΨm in NK cells, correlating with reduced cytotoxicity (r = 0.825, p = 0.0003) and linked to plasma noradrenaline levels (r = -0.578, p = 0.0008) IJMS | Free Full-Text | Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery. This dysfunction is exacerbated in the tumor microenvironment (TME), where cancer cells compete with tumor-infiltrating lymphocytes (TILs), including NK cells, for glucose, forcing NK cells to rely more on OXPHOS and making them vulnerable to metabolic stress Role of mitochondrial alterations in human cancer progression and cancer immunity.

In metastatic breast cancer, NK cells exhibit dysfunctional mitochondria, with increased mitochondrial mass but disrupted relationships with mitochondrial membrane potential, suggesting pathology-induced metabolic stress TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer | Journal for ImmunoTherapy of Cancer. This indicates that mitochondrial health is a critical determinant of NK cell function, and its impairment can be a leading cause of dysfunction in cancer settings.

p53 as a Central Regulator

The tumor suppressor p53 is a transcription factor that regulates numerous cellular processes, including mitochondrial function and immune surveillance. In healthy cells, p53 promotes mitochondrial integrity by upregulating genes involved in OXPHOS, antioxidant defense, and mitochondrial biogenesis TP53 Mutation, Mitochondria and Cancer. However, in cancer, p53 is frequently mutated, with over 50% of human tumors showing TP53 mutations, leading to loss of function and sometimes gain-of-function oncogenic properties p53 - Wikipedia.

p53 mutations result in mitochondrial dysfunction in cancer cells, shifting metabolism toward glycolysis (Warburg effect) and increasing the production of immunosuppressive metabolites like lactate. This metabolic reprogramming is evident in studies showing that mutant p53 (p53Mut) enhances mitochondrial oxidation in aggressive cancer stem cells, correlating with morphological changes in mitochondria Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy. This altered metabolism contributes to an immunosuppressive TME, which can indirectly impair NK cell mitochondrial function by limiting nutrient availability and increasing oxidative stress.

Moreover, p53 directly influences NK cell recognition of cancer cells by regulating the expression of NKG2D ligands ULBP1 and ULBP2. Research demonstrates that induction of wild-type p53 upregulates mRNA and cell surface expression of ULBP1 and ULBP2, enhancing NKG2D-dependent degranulation and IFN-γ production by NK cells Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2 | Cancer Research | American .... This regulation occurs through intronic p53-responsive elements, highlighting the importance of p53's intron 1 and coding DNA in immune surveillance. In contrast, mutant p53 fails to upregulate these ligands, allowing cancer cells to evade NK cell attack and contributing to tumor progression.

Transposable Elements and Viruses: Disruptors of p53 Function

Transposable elements, such as endogenous retroviruses (ERVs) and long interspersed nuclear elements (LINEs), and viruses can significantly disrupt p53's regulatory network. Studies have identified p53 binding sites within transposons, with approximately 35% of p53 binding sites residing in LTR, LINE, and DNA transposons P53 Binding Sites in Transposons. For instance, ERVs account for 30% of p53 binding sites, and p53 regulates nearby genes, suggesting a role in genome stability Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53 | PNAS. When p53 is mutated or dysfunctional, these elements can become derepressed, leading to genetic instability and increased transposition, which can insert into critical regulatory regions like intron 1 of TP53, disrupting its function.

Viruses, particularly retroviruses, can integrate into the host genome and alter p53 binding sites, further impairing its activity. For example, viral miRNAs from Epstein-Barr virus (EBV) target cellular transcripts, including those involved in immune recognition, potentially affecting p53's regulation of ULBP1 and ULBP2 P53 Transposable Elements and Regulatory Introns Inform Codondex Cell Selection for Autologous Trigger of Immune Cascade | bioRxiv. This disruption can lead to a loss of p53's tumor-suppressive functions, promoting cancer cell survival and immune evasion.

Downstream Genetic Causes and Autoimmune Cell Spread

The downstream genetic causes, driven by transposable elements and viruses, exacerbate p53 dysfunction, leading to increased genomic instability. This instability can result in chromosomal rearrangements and the activation of oncogenes, creating a permissive environment for cancer progression. For instance, loss of p53 and RB in mouse embryonic fibroblasts leads to epigenetic changes and upregulation of LINE and SINE transposable elements, correlating with increased tumorigenesis P53 and RB Cooperate to Suppress Transposable Elements | bioRxiv. This genetic disruption can also affect genes involved in mitochondrial function, further altering the TME and impairing NK cell activity.

The spread of autoimmune cells, potentially linked to this genetic instability, may be facilitated by the failure of NK cells to eliminate aberrant cells due to mitochondrial dysfunction and p53-related immune evasion. The altered TME, rich in immunosuppressive cytokines like IL-6 and TGF-β, further suppresses NK cell function, creating a feedback loop that promotes cancer and autoimmune cell proliferation.

The Role of Intron 1 and ULBP1/2 in Homeostasis

Intron 1 of p53 is particularly significant, as it contains regulatory elements that influence p53's transcriptional activity, including the regulation of ULBP1 and ULBP2. Research shows that p53-responsive elements in the introns of ULBP1 and ULBP2 are critical for their upregulation, enhancing NK cell recognition Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2 - PubMed. Disruptions in this region, such as insertions by transposable elements, can impair p53's ability to control these ligands, leading to reduced NK cell activity and increased cancer cell escape from innate immunity.

This failure to maintain homeostasis, driven by p53 dysfunction and mitochondrial stress, allows cancer cells to proliferate and metastasize, retaining genetic instability through mitosis and contributing to tumor conditions. The interplay between p53's control of transposons and its regulation of mitochondrial function further amplifies this effect, creating a complex network of dysfunction.

Conclusion

The evidence suggests that mitochondria are a leading cause of NK cell dysfunction in cancer, driven by p53 mutations that alter cancer cell metabolism and impair immune recognition through ULBP1 and ULBP2. Transposable elements and viruses exacerbate this by disrupting p53's regulatory network, leading to genetic instability and a hostile TME. The role of intron 1 in p53's regulation of ULBP1/2 is critical, and its disruption can further impair homeostasis, promoting tumor conditions. This complex interplay underscores the need for further research into targeted therapies that restore p53 function and mitochondrial health to enhance NK cell activity.

---

Key Citations

• Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery
• Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2
• TP53 Mutation, Mitochondria and Cancer
• P53 Binding Sites in Transposons
• Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53
• Role of mitochondrial alterations in human cancer progression and cancer immunity
• TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer